SPRY Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
33.7M
+48.4%
22.7M
-19.2%
28.1M
-13.6%
32.5M
+106.8%
15.7M
Cost of Revenue
12.8M
+104.4%
6.3M
+2.1%
6.2M
-24.9%
8.2M
+64.3%
5.0M
Gross Profit
20.8M
+26.9%
16.4M
-25.2%
21.9M
-9.8%
24.3M
+126.5%
10.7M
Operating Expenses
82.3M
+7.5%
76.5M
+20.7%
63.4M
-18.2%
77.5M
+32.8%
58.3M
R&D
4.7M
+8.3%
4.3M
+25.9%
3.4M
+25.2%
2.8M
-31.8%
4.0M
SG&A
77.6M
+7.4%
72.2M
+20.4%
60.0M
-19.8%
74.8M
+37.6%
54.3M
Operating Income
-61465000
-2.2%
-60145000
-45.1%
-41465000
+22.0%
-53192000
-11.7%
-47614000
EBITDA
-61049000
-2.2%
-59748000
-45.6%
-41048000
+22.3%
-52801000
-11.5%
-47335000
Net Income
-62339000
-2.8%
-60618000
-47.5%
-41097000
+19.6%
-51112000
-13.9%
-44883000
EPS (Basic)
$-0.63
-3.3%
$-0.61
-48.8%
$-0.41
+21.2%
$-0.52
-13.0%
$-0.46
EPS (Diluted)
$-0.63
-3.3%
$-0.61
-48.8%
$-0.41
+21.2%
$-0.52
-13.0%
$-0.46
Shares (Diluted)
99.3M
+0.0%
99.3M
+0.3%
99.0M
+0.2%
98.8M
+0.5%
98.4M
ARS Pharmaceuticals (SPRY) โ€” Financials